The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2023 | The use of genomics to help select treatment in CLL
Thomas Kipps, MD, PhD, UC San Diego, Moores Cancer Center, La Jolla, CA, explains how genomics may be used to help with treatment decisions in chronic lymphocytic leukemia (CLL). Dr Kipps notes that some genetic factors are predictive of poor response to a specific therapy while others may be predictive of poorer outcomes regardless of therapy choice. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
